 |
Name: Editas Medicine Location: Cambridge, Massachusetts What it Does: Uses genome editing, which allows sequence-targeted modification of DNA to potentially switch off or modify disease-creating genes to create new class of genomic medicine. GV Participation: New investor in $120 million Series B round. GV Investor: Krishna Yeshwant |
0 comments
Hide comments
